Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethyl dibunate is a non-narcotic antitussive agent that was used for the symptomatic relief of acute and chronic cough. Chemically, it is the ethyl ester of 2,6-di-tert-butylnaphthalene-1-sulfonic acid. It was developed as an alternative to codeine-based cough suppressants, offering the benefit of being non-addictive and lacking respiratory depressant effects. While its precise molecular mechanism is not fully elucidated in modern terms, it acts to suppress the cough reflex. The drug was studied and marketed in the 1960s but has largely been superseded by other antitussive agents in contemporary clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethyl dibunate.